Product Images Capecitabine

This is a drug for oral administration presented in the form of film-coated tablets that contain 150 mg of the active ingredient capecitabine, USP. The dosage and other relevant information can be found in the accompanying prescribing information. The tablets should not be crushed or cut and should be kept in a tight, light-resistant container with a child-resistant closure. It should be kept out of reach of children and stored at controlled room temperature in accordance with USP guidelines. The drug is manufactured by Teva Czech Industries and marketed by GSMS, Incorporated. Patient information can be found on https://gsms.us/.*

This is a medication called Capecitabine, available in 500mg tablets. The dosage instructions can be found in the accompanying prescribing information, and the tablets should not be crushed or cut. It should be stored in a tightly closed, light-resistant container out of reach of children at controlled room temperature. The medication is manufactured by Teva Czech Industries and marketed by GSMS, Inc. It is a cytotoxic agent. The pharmacist should dispense patient information to each patient, and it can be printed from the website https://gsms.us/.*

This is a treatment plan for cancer patients, specifically using two different chemotherapy regimens. The first one is 5-FU (fluorouracil) combined with Leucovorin using the Mayo Regimen. The second regimen involves the drug Capecitabine, with a dosage of 1250 mg/sqm taken twice a day on an intermittent schedule. The graph shows the time in days along with corresponding doses of the Capecitabine regimen.*

This document provides a table of estimated probability values for a medical treatment plan involving Docetaxel and Capecitabine. The table lists the probability values for different drug dosages and timeframes in relation to the treatment's effectiveness. The dosages are presented in milligrams per square meter while the timeframes are given in days. The text also includes a chart that displays the relationship between the time duration of the treatment and the response rate of the treatment. The treatment was given in three weekly cycles.*